Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Probiodrug to Attend and Present at European Conferences in May 2016 | ||
By: Nasdaq / GlobeNewswire - 03 May 2016 | Back to overview list |
|
Probiodrug to Attend and Present at European Conferences in May 2016 HALLE/SAALE, Germany, 3 May 2016 - Probiodrug AG ("Probiodrug", Euronext: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer's disease, announces that the company is scheduled to attend the following conferences:
(1)
Bio€quity Europe 2016
Dr Hendrik Liebers, CFO, to present on Tuesday, 10 May at 11:40 am CET in Ball Room 1 Now in its 17th year, Bio€quity Europe is a major industry event for financial dealmakers looking for investor-validated life science companies and for pharmaceutical licensing professionals to assess top prospects. Bio€quity Europe has showcased more than 700 leading European companies to thousands of investment and pharma business development professionals. Delegates from over 20 nations attended the event last year.
(2)
analytica 2016
Dr Hendrik Liebers, CFO, to join the panel on Thursday, 12 May, at 03:30 pm CET entitled: "Biotech and the stock exchange: A marriage of convenience or elite partners?" The analytica conference aims to promote interactions between scientists and industry representatives to enable interdisciplinary collaboration on an international level. The Finance Day on Thursday, 12 May, will enable biotech entrepreneurs to meet with investors. Speakers will discuss the latest financing trends as well as collaborations between big pharma and biotech companies. This year's program will focus on which financing alternatives are best for companies and tips on how to enter the US market. ### For more information, please contact:
Probiodrug
Hume Brophy
Notes to Editors:
Founded in 1997, the company successfully developed a novel therapeutic concept for diabetes - the DP4 inhibitors - which provided the basis for a novel class of antidiabetics - the gliptins. Its core capabilities are based on its long-standing expertise in the elucidation of the structure and function of enzymes involved in the modification of proteins and peptides, which play a central role in pathological conditions.
Today Probiodrug's aim is to become a leading company in the development of Alzheimer's disease treatments and to thereby provide a better life for Alzheimer's disease patients. It has identified a new therapeutic concept linked to disease initiation and progression. The development approaches are targeting pyroglutamate-Abeta (pGlu-Abeta) as a therapeutic strategy to fight Alzheimer's disease. The Company has medical use and composition of matter patents related to the inhibition of Glutaminyl Cyclase (QC) and anti-pGlu-Abeta- specific monoclonal antibodies, providing it, in the Company's view, with a leading position in this field of research.
About Alzheimer's disease
Forward Looking Statements
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Probiodrug via GlobeNewswire
HUG#2009176
|
||
|
||
Copyright 2016 Nasdaq / GlobeNewswire | Back to overview list |